Article excerpt
When a bioactive molecule occurs in nature at trace levels, traditional extraction often means sifting through mountains of biomass for a few grams of material. This model fails when the target compound is ultra-rare, especially when hunting for non-psychoactive cannabinoid-type molecules for medicinal use that nature hides in tiny yields, mixed with the illegal and psychoactive compounds like THC. eXoZymes started from the recognition that many valuable compounds are simply inaccessible at commercial scale by petrochemical synthesis or plant extraction.
Here the spotlight falls on Cannabinoid Program Director John Billingsley, who oversees the “BioClick” enzyme-engineering initiative at eXoZymes. He puts it succinctly: “Our new BioClick approach opens the door to the biomanufacturing of rare and previously unthinkable target molecules that can be game-changers in medicine, nutrition, and other functional nutraceuticals.”
For the non-psychoactive cannabinoid world this means: being able to produce ultra rare or new‐to‐nature cannabinoids in a steel bioreactor, rather than harvesting hemp residues or performing complex chemical synthesis. The technology promises to unlock molecules that were previously simply uncommercial or inaccessible.
eXoZymes Safe Harbor
This article includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “potential,” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this article regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.